Understanding Arrhythmogenic Cardiomyopathy: Advances through the Use of Human Pluripotent Stem Cell Models

Christianne J Chua1, Justin Morrissette-McAlmon1, Leslie Tung1

  • 1Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Genes
|October 28, 2023
PubMed

Insights

Desmosome-related arrhythmogenic cardiomyopathy (dACM) is a genetic heart condition. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer a promising model for studying dACM and developing new therapies.

Area of Science:

  • Cardiovascular Genetics
  • Stem Cell Biology
  • Molecular Cardiology

Background:

  • Cardiomyopathies (CMPs) are a major cause of heart failure and premature death.
  • Arrhythmogenic cardiomyopathy (ACM) has a strong genetic basis, with variants in desmosome genes causing desmosome-related ACM (dACM).
  • dACM can lead to sudden cardiac death and myocardial fibrofatty infiltrates.

Purpose of the Study:

  • To review the current understanding of dACM.
  • To summarize findings from various model systems of dACM.
  • To highlight the utility and progress of human induced pluripotent stem cell-cardiomyocyte (hiPSC-CM) models in dACM research.

Main Methods:

  • Review of existing literature on dACM and its genetic basis.
  • Analysis of findings from animal and primary human cell models.
  • Synthesis of research utilizing hiPSC-CMs for dACM modeling.

Main Results:

  • Desmosome gene variants are established causes of dACM.
  • Previous model systems have limitations in recapitulating human dACM.
  • hiPSC-CMs provide a scalable and reproducible platform to model patient-specific dACM phenotypes.
  • Novel insights into dACM mechanisms have emerged from hiPSC-CM studies.

Conclusions:

  • hiPSC-CMs are a powerful tool for advancing dACM research.
  • Further research using hiPSC-CMs is crucial for understanding disease mechanisms and developing therapeutic strategies.
  • Future directions include refining hiPSC-CM models and exploring novel therapeutic targets for dACM.